Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TVTX POWR Grades
- Value is the dimension where TVTX ranks best; there it ranks ahead of 72.39% of US stocks.
- The strongest trend for TVTX is in Momentum, which has been heading up over the past 178 days.
- TVTX's current lowest rank is in the Growth metric (where it is better than 8.79% of US stocks).
TVTX Stock Summary
- TVTX's price/sales ratio is 5.88; that's higher than the P/S ratio of 80.47% of US stocks.
- With a year-over-year growth in debt of 82.22%, TRAVERE THERAPEUTICS INC's debt growth rate surpasses 86.32% of about US stocks.
- Revenue growth over the past 12 months for TRAVERE THERAPEUTICS INC comes in at -3.54%, a number that bests merely 19.85% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to TRAVERE THERAPEUTICS INC, a group of peers worth examining would be TDUP, FBIO, HCWB, APM, and OVID.
- Visit TVTX's SEC page to see the company's official filings. To visit the company's web site, go to www.retrophin.com.
TVTX Valuation Summary
- TVTX's price/sales ratio is 6; this is 20% higher than that of the median Healthcare stock.
- TVTX's EV/EBIT ratio has moved down 4.8 over the prior 121 months.
Below are key valuation metrics over time for TVTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TVTX | 2022-12-02 | 6.0 | 12.8 | -4.9 | -6.2 |
| TVTX | 2022-12-01 | 5.9 | 12.5 | -4.7 | -6.0 |
| TVTX | 2022-11-30 | 6.1 | 12.8 | -4.9 | -6.2 |
| TVTX | 2022-11-29 | 5.7 | 12.1 | -4.6 | -5.9 |
| TVTX | 2022-11-28 | 5.7 | 12.1 | -4.6 | -5.9 |
| TVTX | 2022-11-25 | 5.9 | 12.4 | -4.7 | -6.0 |
TVTX Growth Metrics
- The 4 year price growth rate now stands at -23.02%.
- The year over year net income to common stockholders growth rate now stands at 9.78%.
- The 4 year revenue growth rate now stands at 37.39%.
The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 213.399 | -158.528 | -264.232 |
| 2022-06-30 | 228.12 | -86.94 | -230.215 |
| 2022-03-31 | 228.57 | -43.638 | -202.195 |
| 2021-12-31 | 227.49 | -14.792 | -180.091 |
| 2021-09-30 | 221.224 | -1.785 | -250.14 |
| 2021-06-30 | 204.146 | -27.113 | -237.05 |
TVTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
- TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
- VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.
The table below shows TVTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.306 | 0.969 | -0.399 |
| 2021-06-30 | 0.291 | 0.968 | -0.396 |
| 2021-03-31 | 0.289 | 0.968 | -0.412 |
| 2020-12-31 | 0.311 | 0.969 | -0.361 |
| 2020-09-30 | 0.304 | 0.970 | -0.166 |
| 2020-06-30 | 0.303 | 0.967 | -0.194 |
TVTX Price Target
For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.25 (Strong Buy) |
TVTX Stock Price Chart Interactive Chart >
TVTX Price/Volume Stats
| Current price | $20.01 | 52-week high | $31.65 |
| Prev. close | $20.08 | 52-week low | $18.70 |
| Day low | $19.69 | Volume | 645,609 |
| Day high | $20.33 | Avg. volume | 756,744 |
| 50-day MA | $22.06 | Dividend yield | N/A |
| 200-day MA | $24.68 | Market Cap | 1.28B |
Travere Therapeutics, Inc. (TVTX) Company Bio
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.
Latest TVTX News From Around the Web
Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 173,000 shares of its common stock to 12 new employees, consisting of inducement stock options to purchase an aggregate of 90,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 83,000 shares of its common stock |
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney DiseaseDeveloped in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences, educate the public, |
Travere Therapeutics to Present at Upcoming Investor ConferencesSAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare ConferenceWednesday, November 16, 2022, at 4:25 p.m. GMT (11:25 a.m. ET) 5th Annual Evercore ISI HealthCONx ConferenceTuesday, November 29, 2022, at 1:25 p.m. ET Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 10:30 a.m. ET BofA Securities 2022 Biotech SMID Cap Conf |
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Travere Therapeutics (TVTX) and Karuna Therapeutics (KRTX)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chimerix (CMRX – Research Report), Travere Therapeutics (TVTX – Research Report) and Karuna Therapeutics (KRTX – Research Report) with bullish sentiments. Chimerix (CMRX) JonesTrading analyst Soumit Roy reiterated a Buy rating on Chimerix today and set a price target of $5.00. The company's shares closed last Thursday at $1.86, close to its 52-week low of $1.27. According to TipRanks. |
Travere Therapeutics Reports Third Quarter 2022 Financial ResultsEMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for the third quarter of 2022 SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2022 financial results and provided a corporate update. European Medicines Age |
TVTX Price Returns
| 1-mo | -3.61% |
| 3-mo | -22.41% |
| 6-mo | -12.92% |
| 1-year | -27.53% |
| 3-year | 50.90% |
| 5-year | N/A |
| YTD | -35.53% |
| 2021 | 13.89% |
| 2020 | 91.94% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...